ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0197

Development of a Chikungunya Arthritis Disease Activity Score

Aileen Chang1, Samuel Simmens1, Hugh Watson2, Richard Amdur3, Andre Siqueira4, Abigale Proctor1, Sarah Tritsch1, Carlos Herrera1, Liliana Encinales5, Alfonso Sucerquia1, Alejandro Jaller1, Juan Jose Jaller6, Kennedy Amaral7, Gary Simon1, Larry Moreland8, Andres Cadena9 and Gary Firestein10, 1George Washington University, Washington, DC, 2Evotec, Lyon, France, 3Northwell, Washington, DC, 4Fiocruz, Rio, Brazil, 5Allied Research Society, Barranquilla, Colombia, 6Reumatologos SAS, Barranquilla, Colombia, 7Institute of Diagnostic Medicine of Cariri, Pernambuco, Brazil, 8University of Colorado, Denver, CO, 9Clinica de la Costa, Barranquilla, Colombia, 10University of California San Diego, San Diego, CA

Meeting: ACR Convergence 2023

Keywords: Arthritis, Infectious, autoimmune diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0196–0228) Infection-related Rheumatic Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Chikungunya virus is an alphavirus spread by mosquitos that causes a debilitating chronic arthritis that has no standard treatment to date. The objective of this expert group was to develop a measure of chikungunya arthritis that would be useful for clinical trials and patient care.

Methods: A group of chikungunya experts, rheumatologists and biostatisticians identified component measures for evaluation for inclusion in a chikungunya arthritis disease activity score (CHIK-DAS). Utilizing data from a Colombian cohort of chikungunya arthritis patients (N=84), linear regression was used to identify the components that were independently associated with patient reported outcomes assessing disability, pain, physical and mental quality of life and mobility. A preliminary instrument was developed and assessed for internal consistency and test-retest reliability. Cutoffs for grading disease severity were determined.

Results: A CHIK-DAS was developed including a 30 tender joint count and a stiffness item in a form with and without CRP. Disease activity was defined as remission (< 0.22), mild (< 0.75), moderate (0.75-1.29) and severe (≥1.30) disease.

Conclusion: The CHIK-DAS may be used as a specific measure of disease activity in chikungunya arthritis in clinical trials and patient care. This metric should be further validated in additional cohorts.

Supporting image 1

Chikungunya Disease Activity Score (CHIK-DAS). The items 30 tender joint count including the 28 joints from the DAS_28 and the ankle joints and a stiffness score with and without C-reactive protein. The 28 joints included in the DAS_28 are the bilateral shoulders, elbows, wrists, metacarpophalangeal, proximal interphalangeal and knees.


Disclosures: A. Chang: None; S. Simmens: None; H. Watson: Evotec, 3; R. Amdur: None; A. Siqueira: None; A. Proctor: None; S. Tritsch: None; C. Herrera: None; L. Encinales: None; A. Sucerquia: None; A. Jaller: None; J. Jaller: None; K. Amaral: None; G. Simon: None; L. Moreland: Boehringer-Ingelheim, 12, member of independent Data Safety Monitoring Board, Celltrion, 12, member of independent Data Safety Monitoring Board; A. Cadena: None; G. Firestein: Eli Lilly, 5.

To cite this abstract in AMA style:

Chang A, Simmens S, Watson H, Amdur R, Siqueira A, Proctor A, Tritsch S, Herrera C, Encinales L, Sucerquia A, Jaller A, Jaller J, Amaral K, Simon G, Moreland L, Cadena A, Firestein G. Development of a Chikungunya Arthritis Disease Activity Score [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/development-of-a-chikungunya-arthritis-disease-activity-score/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-chikungunya-arthritis-disease-activity-score/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology